Tango Therapeutics, Inc. (TNGX) Reports In-Line Q2 EPS

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $3.18 million versus the consensus estimate of $6.42 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c
• Pan American Silver (PAAS) Misses Q2 EPS by 19c